Try our Advanced Search for more refined results

Wang et al v. Ampio Pharmaceuticals, Inc. et al

  1. February 21, 2025

    Pharma Co. Investors Get Final OK For $3M Settlement

    Investors in Colorado pharmaceutical company Ampio have gotten final approval for their $3 million deal resolving claims that its leadership mishandled a clinical trial for the company's sole drug candidate and distributed the drug outside the trial for unapproved use, leading to an internal investigation in which two executives were fired and a disclosure that there was "no clinical pathway forward" for the treatment.

  2. August 10, 2023

    Faruqi & Faruqi Will Lead Investors In COVID Drug Claims Suit

    Faruqi & Faruqi LLP secured its role as the lead counsel in a proposed class action alleging executives at Colorado-based Ampio Pharmaceuticals Inc. misled investors with false optimism on the potential that its anti-inflammatory drug could treat long-term COVID-19 symptoms.

  3. November 09, 2022

    Firm Touts Diversity In Bid To Lead COVID Drug Claims Suit

    Faruqi & Faruqi LLP has touted its minority and woman ownership in its bid to lead an investor suit against Ampio Pharmaceutical Inc. over its executives' claims about a COVID-19 drug, while another movant in the case has said the firm's client may have ties to Ampio.

  4. October 18, 2022

    Five Firms Vie To Lead Investor Suit On COVID Drug Claims

    Five firms, including the Rosen Law Firm PA and Pomerantz LLP, are vying to represent a group of investors in a suit accusing executives at Colorado-based Ampio Pharmaceutical Inc. of misleading shareholders about the efficacy of a drug they said could treat COVID-19.

  5. August 19, 2022

    Colo. Pharma Co. Faces Securities Suit Over Drug Claims

    Colorado pharmaceutical company Ampio is facing a proposed shareholder class action accusing the firm's executives of making false and misleading claims about the efficacy of its star drug, Ampion, which it billed as a potential treatment for long COVID-19.